Archive for the ‘Chief executive officer’ Category

Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma

ROCKVILLE, Md., Aug 17, 2011 –
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical(TM) protein therapeutic in development for [...]

August 24, 2011  Tags: , , ,   Posted in: Chief Medical Officer, Chief executive officer, Clinical Research, Clinical trial, Emergent BioSolutions, Health Care, fuad el-hibri  No Comments

Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference

ROCKVILLE, Md., Aug 09, 2011 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at 10:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]

August 15, 2011  Tags: , , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, Investors, fuad el-hibri  No Comments

Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax

ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]

July 7, 2011  Tags: , , , , ,   Posted in: Biothrax, Chief executive officer, Emergent BioSolutions, Health Care, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors

ROCKVILLE, Md., Jun 13, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its Chairman and Chief Executive Officer, Fuad El-Hibri, has been appointed to serve on the Board of Directors of the U.S. Chamber of Commerce. The U.S. Chamber of Commerce is the world’s largest business federation representing the interests of more [...]

June 20, 2011  Tags: , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, entrepreneur, fuad el-hibri  No Comments

Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]

June 10, 2011  Tags: , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, NuThrax, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]

June 7, 2011  Tags: , , , , ,   Posted in: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions Reports Financial Results for First Quarter 2011

ROCKVILLE, Md., May 05, 2011 (BUSINESS WIRE) — Emergent BioSolutionsInc. (NYSE: EBS) announced  its financial results for the first quarter ended March 31, 2011.
For 1Q 2011, total revenues were $18.5 million as compared to $46.8 million in 2010. In addition, for 1Q 2011 the company recorded a net loss of $21.4 million, or $0.61 per [...]

May 12, 2011  Tags: , , , , ,   Posted in: BioDefense, Biothrax, Business, Chief executive officer, Chief financial officer, Revenue  No Comments

Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial

Total of 2,784 infants vaccinated in TB efficacy trial evaluating MVA85A
Study results expected to be available as early as mid-2012

ROCKVILLE, Md., Apr 28, 2011
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its joint venture with the University of Oxford (Oxford), the Oxford-Emergent Tuberculosis Consortium [...]

May 2, 2011  Tags: , ,   Posted in: Chief executive officer, Emergent BioSolutions, South Africa  No Comments

Emergent BioSolutions Reports Financial Results for Full Year 2010

2010 revenues of $286.2 million
2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability
2010 cash, investments and accounts receivable balance of $210.4 million
2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million

Emergent BioSolutions Inc. (NYSE: EBS) announced on 10 March its [...]

April 13, 2011  Tags: , , , , ,   Posted in: Board of Directors, Business, Chief executive officer, Emergent BioSolutions, Financial Results, fuad el-hibri  No Comments